In early March 2026, Tango Therapeutics and Erasca announced a clinical trial collaboration and supply agreement to test Erasca’s pan-RAS molecular glue ERAS-0015 with Tango’s PRMT5 inhibitor ...
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, ...
Zacks Investment Research on MSN
TNGX stock hits record high on inking collaboration deal with ERAS
Shares of Tango Therapeutics TNGX surged 36.3% on Thursday to a record high after Erasca ERAS announced a clinical trial collaboration and supply agreement with the company. Under the agreement, the ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...
Two companion studies published in Cancer Research from scientists at Moffitt Cancer Center identify distinct but complementary approaches to overcoming drug resistance in KRAS G12C–mutant non-small ...
Preclinical study offers foundation for a combination strategy in future clinical trials In this study, the researchers used RAS(ON) multi-selective inhibitors, the investigational agent daraxonrasib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results